Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis.
about
Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival.Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: Case reportProgressive hypoventilation due to mixed CD8+ and CD4+ lymphocytic polymyositis following tremelimumab - durvalumab treatment.Melanoma of the oral cavity: pathogenesis, dermoscopy, clinical features, staging and management.Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody.Enhancing the treatment effect on melanoma by heat shock protein 70-peptide complexes purified from human melanoma cell lines.Update on primary head and neck mucosal melanoma.Clinics, prognosis and new therapeutic options in patients with mucosal melanoma: A retrospective analysis of 75 patients.Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN).Pembrolizumab: a novel antiprogrammed death 1 (PD-1) monoclonal antibody for treatment of metastatic melanoma.Interleukin-2, Ipilimumab, and Anti-PD-1: Clinical Management and the Evolving Role of Immunotherapy for the Treatment of Patients With Metastatic Melanoma.Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis.Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review.Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab.Ipilimumab in melanoma.Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.Pembrolizumab use for the treatment of advanced melanoma.Acute interstitial nephritis related to immune checkpoint inhibitors.Safety and efficacy of nivolumab in the treatment of cancers: A meta-analysis of 27 prospective clinical trials.A Case of Nivolumab-Induced Myositis.Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapyEndocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management.Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review.Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial.Anorectal mucosal melanoma.Immune-related endocrine disorders in novel Immune checkpoint inhibition therapy.A single-institution study examining cutaneous and non-cutaneous melanomas treated with nivolumab.Immunotherapy in mucosal melanoma: a case report and review of the literature.
P2860
Q30240748-6074A4AC-6AA5-4FD1-A04B-E1F06F59FE39Q30275870-D67AA289-8179-4F76-AB77-7553822C21BFQ33885794-AAADCCA1-B01C-414C-B72D-FF259AD1E205Q33913077-66A375B1-7AD3-4A4F-8024-B815A01620CDQ34331179-2EE47AEA-683B-4FBE-A2D4-E11D4F43B6D2Q36539682-8859A97C-C390-4B35-9D8B-2182B3C4F6F9Q37024301-19039926-9D2F-4A82-A4AF-29814D9A17F7Q37142487-50E412A3-50C0-4C97-B711-2E3C9AB92ADCQ37178922-C20702D2-F783-4724-B7B5-DA54D48A7E07Q37582623-E9C02ACE-B9E2-453A-9279-DE0196B0C90CQ38367232-1C88EB9D-EAE9-4AB0-94D1-E2DA202DDBBDQ38540340-C5176F94-8F82-4495-B453-B2817B3B217EQ38595251-0B3C463E-0BD8-449B-B252-E2F2C48124A9Q38699309-EBC7E81C-AC7A-460D-862C-5A1DD714443FQ38783026-9497D2E8-AE79-4D35-B48A-119CE85E4314Q38804604-C285A0C3-2B8B-4FB3-93CF-8416B36504DFQ38893697-3CC9CA48-E378-4969-AFC4-666108D984C5Q39038191-087E83FC-C1C5-4F04-8D96-CBC11C558D29Q39190201-FD412AA0-9B6E-43F0-9C3E-88B9DD4734FBQ39198197-2638ADF5-68A8-4D6F-A748-84E634C85C94Q39215902-CD33EDF6-6117-4D5F-9BC3-7D8C68C80811Q42353620-1A6646B0-815D-466F-9A74-90FE83B587CAQ42354162-D2BCF26F-8706-44EB-9750-9856FD296749Q48289680-529D20FB-A0A9-4A2E-89DC-D29EAA4B0E6FQ49188770-7F3A086A-8095-4183-91A0-AE56ED80EDB6Q51529309-75F8D8B4-B82C-4763-B7F1-9B654E6B133EQ52680468-AA8403A3-BDE9-4AAB-9B9D-9E17C6852145Q53656848-9612A012-2CCE-4E71-8C3F-3B77A238B533Q54671330-04B0F3E8-957F-452B-BC94-F2773E27D606Q55053720-8A694C76-EC6A-45E4-93DA-7CB288BE9F39
P2860
Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis.
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Anti-PD1 following ipilimumab ...... thyroidism and rhabdomyolysis.
@ast
Anti-PD1 following ipilimumab ...... thyroidism and rhabdomyolysis.
@en
Anti-PD1 following ipilimumab ...... thyroidism and rhabdomyolysis.
@nl
type
label
Anti-PD1 following ipilimumab ...... thyroidism and rhabdomyolysis.
@ast
Anti-PD1 following ipilimumab ...... thyroidism and rhabdomyolysis.
@en
Anti-PD1 following ipilimumab ...... thyroidism and rhabdomyolysis.
@nl
prefLabel
Anti-PD1 following ipilimumab ...... thyroidism and rhabdomyolysis.
@ast
Anti-PD1 following ipilimumab ...... thyroidism and rhabdomyolysis.
@en
Anti-PD1 following ipilimumab ...... thyroidism and rhabdomyolysis.
@nl
P2860
P1476
Anti-PD1 following ipilimumab ...... thyroidism and rhabdomyolysis.
@en
P2093
F Stephen Hodi
P2860
P356
10.1158/2326-6066.CIR-13-0146
P577
2013-10-07T00:00:00Z